CDIO is trading 2.7% down at $2.14 as investors take profits following yesterday's sharp 11.7% rally, despite positive news regarding test coverage expansion.
- The company announced that Atlas Healthcare Physicians will cover its Epi+Gen CHD and PrecisionCHD tests, a move expected to broaden patient access.
- Shares fell approximately 10.5% in pre-market trading, suggesting a valuation reassessment and profit-taking rather than a negative reaction to the partnership.
- The current price action follows a period of significant volatility as traders lock in gains from the recent spike.